TY  - BOOK
AU  - Chauhan, Ayushi F
TI  - Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic. [Review]
SN  - 1179-1322
PY  - 2021///
KW  - IN PROCESS -- NOT YET INDEXED
KW  - MedStar Washington Hospital Center
KW  - Hematology and Oncology
KW  - Journal Article
KW  - Review
N2  - The phosphatidylinositol-3-kinase (PI3K) pathway is ubiquitous to multiple cellular processes and is intricately implicated in lymphomagenesis. The development of PI3K inhibitors has broadened treatment options for relapsed and/or refractory follicular lymphoma (FL) and currently three PI3K inhibitors have been approved in the third-line setting for FL, including idelalisib (oral), duvelisib (oral), and copanlisib (intravenous), with other agents under investigation. In this review, we discuss the clinical advance of copanlisib through preclinical to Phase III trials, its unique cellular targets and side effect profile that have poised it as a safer and equally efficacious option when compared to the older-generation oral PI3Kis, and its utility to the clinician as part of the therapeutic armamentarium for relapsed and/or refractory FL. Copyright (c) 2021 Chauhan and Cheson
UR  - https://dx.doi.org/10.2147/CMAR.S201024
ER  -